US-based Cardio Diagnostics has forged a collaboration with concierge medicine practice RiverRock Medical to launch the former’s epigenetic-genetic heart disease testing in Austin, Texas, US.
Through the partnership, RiverRock Medical will become the first service provider in Texas to incorporate Epi+Gen CHD and PrecisionCHD, which are advanced epigenetic-genetic heart disease risk and detection technologies.
Both the tests, which will combine epigenetics, genetics, and artificial intelligence, will be accessible to all the patients of RiverRock Medical.
Additionally, the agreement will provide the practice with access to the Actionable Clinical Intelligence platform that connects the underlying Deoxyribonucleic acid (DNA) methylation and single nucleotide polymorphism biomarkers measured by the PrecisionCHD and Epi+Gen CHD tests to coronary heart disease (CHD) drivers.
RiverRock Medical founder Zain Hakeem said: “Our collaboration with Cardio Diagnostics offers an exciting opportunity to uplift the standards of patient care through greater precision and customisation.
“At RiverRock, we acknowledge and value the uniqueness of each individual’s health journey and strive to reflect this in our healthcare delivery. With the integration of advanced epigenetic-genetic heart disease risk and detection technologies, we’re facilitating a significant progression in the prevention and treatment of cardiovascular disease.
“This enables our patients to gain an in-depth understanding of their unique health risk profile and provides them with actionable insights for effective disease prevention and management.”
RiverRock Medical aims to transform concierge medicine and focus on patient longevity, technological innovation, and medical practices based on evidence.
It is said to take a partnership approach with patients for increased autonomy and offers a personalised care model with an aim to exceed traditional healthcare norms.
Cardio Diagnostics co-founder and chief medical officer Robert Philibert said: “Through the fusion of comprehensive patient data, cutting-edge molecular technologies, and rigorous scientific research, Dr. Hakeem is driving a new standard of healthcare accuracy and personalisation.
“At RiverRock Medical, precision medicine is not simply a trending term—it is an integral principle shaping their dedication to augmenting patient health and longevity.”
The PrecisionCHD test was launched by Cardio Diagnostics last month.
